Given the limited sample size (<i>N</i> = 11), these findings should be interpreted as exploratory; however, they provide hypothesis-generating evidence suggesting that <i>NF1</i> may serve as a potential complementary biomarker in assessing the prognosis of GBM patients in future clinical evaluations. The gene discussed is NF1; the disease is glioblastoma.